Guggenheim on Celldex Therapeutics (CLDX): 'We continue to think today's stock reaction is overdone'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
September 25, 2024 10:45 AM EDT- 71% of patients (150 mg Q4W) achieved complete response at Week 52 -
- Rapid, profound and durable improvement in UAS7 as early as Week 1 with a deepening of response over 52 weeks -
- Robust improvement across omalizumab-experienced/refractory/naïve disease -
- Well tolerated through 52 weeks -
- Enrollment to Global Phase 3 CSU trials underway -
- Company to host webcast today at 12:00 pm ET/6:00 pm CEST -
HAMPTON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today new data... More
